The University of California, Irvine Comprehensive Cancer Center is the only NCI-designated Comprehensive Cancer Center in Orange County and is a matrix-type organization. The Cancer Center serves approximately three million people in Orange County. The research goals of the Cancer Center are: 1) To contribute to the understanding of basic mechanisms that underlie the phenotype and genotype of cancer;2) To facilitate the translation of laboratory and epidemiologic research into hypothesis-driven clinical prevention and treatment studies;3) To conduct clinical prevention trials, whenever possible emanating from research generated in the Center;4) To define cancer risk in the diverse socioeconomic and multicultural society served by the Center and to develop research strategies to facilitate the prevention and early detection of cancer in these populations;and 5) To utilize the extensive education and training opportunities available at all levels as a major translational vehicle and to encourage activities that promote interdisciplinary, multidisciplinary, and transdisciplinary research. The Center is organized into four major Divisions: Basic Sciences, Clinical Research, Cancer Control &Population Sciences, and Education &Training. The Divisions interact through seven research programs: Carcinogenesis, Developmental Biology, Growth Factors &Signaling, Onco-lmaging &Spectroscopy, Population Sciences, Structural Molecular Biology, and Translational Oncology. The Center provides centralized support for Program functions through ten Shared Resource Facilities: Biobehavioral, Biostatistics, Clinical Research Office, DMA Sequencing, DMA &Protein MicroArray, Experimental Tissue, In-Vivo Functional Onco-lmaging, Optical Biology, Protein Mass Spectrometry, and Transgenic Mouse. The Education &Training Division facilitates integration of students into basic, clinical, and cancer control research activities in the various programs and accordingly enhances the translational capabilities of the Center. The 143 full Members of the Center are currently supported by $11,909,249 in direct NCI funds. Of the overall direct total of cancer-related funding ($36,214,529), $30,665,383 is peer-reviewed and $5,549,146 is non-peer-reviewed. Cancer Center Members entered 202 participants on prevention, therapeutic, and supportive care trials in the 2006-07 reporting year.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Parihar, Vipan K; Allen, Barrett D; Tran, Katherine K et al. (2015) Targeted overexpression of mitochondrial catalase prevents radiation-induced cognitive dysfunction. Antioxid Redox Signal 22:78-91
Sun, Peng; Watanabe, Kazuhide; Fallahi, Magid et al. (2014) Pygo2 regulates ?-catenin-induced activation of hair follicle stem/progenitor cells and skin hyperplasia. Proc Natl Acad Sci U S A 111:10215-20
Stockler, Martin R; Hilpert, Felix; Friedlander, Michael et al. (2014) Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32:1309-16
Balu, Mihaela; Kelly, Kristen M; Zachary, Christopher B et al. (2014) Distinguishing between benign and malignant melanocytic nevi by in vivo multiphoton microscopy. Cancer Res 74:2688-97
Lackford, Brad; Yao, Chengguo; Charles, Georgette M et al. (2014) Fip1 regulates mRNA alternative polyadenylation to promote stem cell self-renewal. EMBO J 33:878-89
Watanabe, K; Fallahi, M; Dai, X (2014) Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice. Oncogene 33:632-42
Yonova, Ivelina M; Osborne, Charlotte A; Morrissette, Naomi S et al. (2014) Diaryl and heteroaryl sulfides: synthesis via sulfenyl chlorides and evaluation as selective anti-breast-cancer agents. J Org Chem 79:1947-53
Cheng, Chunmei; Pal, Sukumar; Tifrea, Delia et al. (2014) A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect 16:244-52
Muto, Akihiko; Ikeda, Shingo; Lopez-Burks, Martha E et al. (2014) Nipbl and mediator cooperatively regulate gene expression to control limb development. PLoS Genet 10:e1004671

Showing the most recent 10 out of 289 publications